Enanta Pharmaceuticals
ENTA
ENTA
133 hedge funds and large institutions have $438M invested in Enanta Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 35 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
8% less funds holding
Funds holding: 144 → 133 (-11)
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
46% less capital invested
Capital invested by funds: $805M → $438M (-$367M)
Holders
133
Holding in Top 10
1
Calls
$39K
Puts
$33K
Top Buyers
| 1 | +$6.96M | |
| 2 | +$6.79M | |
| 3 | +$3.75M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.62M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$2.62M |
Top Sellers
| 1 | -$10.7M | |
| 2 | -$8.79M | |
| 3 | -$6.58M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.71M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.66M |